Recent progress in pancreatic cancer

Answer questions and earn CME/CNE

[1]  Cancer Risks in BRCA 2 Mutation Carriers The Breast Cancer Linkage Consortium , 1999 .

[2]  W. Regine,et al.  Analysis of local control in patients receiving IMRT for resected pancreatic cancers. , 2010, International journal of radiation oncology, biology, physics.

[3]  N. Gruis,et al.  Risk of developing pancreatic cancer in families with familial atypical multiple mole melanoma associated with a specific 19 deletion of p16 (p16‐Leiden) , 2000, International journal of cancer.

[4]  Stanley R. Hamilton,et al.  Pathology and genetics of tumours of the digestive system , 2000 .

[5]  K. Kinzler,et al.  Mutant proteins as cancer-specific biomarkers , 2011, Proceedings of the National Academy of Sciences.

[6]  Paul J Keall,et al.  A method to estimate mean position, motion magnitude, motion correlation, and trajectory of a tumor from cone-beam CT projections for image-guided radiotherapy. , 2008, International journal of radiation oncology, biology, physics.

[7]  Michael A. Choti,et al.  DAXX/ATRX, MEN1, and mTOR Pathway Genes Are Frequently Altered in Pancreatic Neuroendocrine Tumors , 2011, Science.

[8]  A. Khorana,et al.  Phase III study comparing gemcitabine plus cetuximab versus gemcitabine in patients with advanced pancreatic adenocarcinoma: Southwest Oncology Group-directed intergroup trial S0205. , 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[9]  D. Silverman,et al.  Pancreatitis and pancreatic cancer risk: a pooled analysis in the International Pancreatic Cancer Case-Control Consortium (PanC4). , 2012, Annals of oncology : official journal of the European Society for Medical Oncology.

[10]  S. Goodman,et al.  K-ras oncogene activation in adenocarcinoma of the human pancreas. A study of 82 carcinomas using a combination of mutant-enriched polymerase chain reaction analysis and allele-specific oligonucleotide hybridization. , 1993, The American journal of pathology.

[11]  Scott E. Kern,et al.  DPC4, A Candidate Tumor Suppressor Gene at Human Chromosome 18q21.1 , 1996, Science.

[12]  K. Campbell,et al.  Analysis of fluorouracil-based adjuvant chemotherapy and radiation after pancreaticoduodenectomy for ductal adenocarcinoma of the pancreas: results of a large, prospectively collected database at the Johns Hopkins Hospital. , 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[13]  M. Saulino,et al.  Polyanalgesic Consensus Conference 2012: Recommendations for the Management of Pain by Intrathecal (Intraspinal) Drug Delivery: Report of an Interdisciplinary Expert Panel , 2012, Neuromodulation : journal of the International Neuromodulation Society.

[14]  S. Goodman,et al.  Very high risk of cancer in familial Peutz-Jeghers syndrome. , 2000, Gastroenterology.

[15]  D. Jäger,et al.  Open-label, multicenter, randomized phase III trial of adjuvant chemoradiation plus interferon Alfa-2b versus fluorouracil and folinic acid for patients with resected pancreatic adenocarcinoma. , 2012, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[16]  Steven P. Cohen,et al.  The Effectiveness of Repeat Celiac Plexus Neurolysis for Pancreatic Cancer: A Pilot Study , 2013, Pain practice : the official journal of World Institute of Pain.

[17]  Jeffrey E. Lee,et al.  Tumor Invasion of Muscular Vessels Predicts Poor Prognosis in Patients With Pancreatic Ductal Adenocarcinoma Who Have Received Neoadjuvant Therapy and Pancreaticoduodenectomy , 2012, The American journal of surgical pathology.

[18]  Daniel Normolle,et al.  A phase I/II trial of intensity modulated radiation (IMRT) dose escalation with concurrent fixed-dose rate gemcitabine (FDR-G) in patients with unresectable pancreatic cancer. , 2012, International journal of radiation oncology, biology, physics.

[19]  L. Traverso,et al.  Interferon-based adjuvant chemoradiation therapy after pancreaticoduodenectomy for pancreatic adenocarcinoma. , 2003, American journal of surgery.

[20]  R. Abrams,et al.  Fluorouracil-based Chemoradiation with Either Gemcitabine or Fluorouracil Chemotherapy after Resection of Pancreatic Adenocarcinoma: 5-Year Analysis of the U.S. Intergroup/RTOG 9704 Phase III Trial , 2011, Annals of Surgical Oncology.

[21]  Jeffrey E. Lee,et al.  Perineural and Intraneural Invasion in Posttherapy Pancreaticoduodenectomy Specimens Predicts Poor Prognosis in Patients With Pancreatic Ductal Adenocarcinoma , 2012, The American journal of surgical pathology.

[22]  Jeffrey E. Lee,et al.  Preoperative gemcitabine and cisplatin followed by gemcitabine-based chemoradiation for resectable adenocarcinoma of the pancreatic head. , 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[23]  Vikesh K. Singh,et al.  Comparative analysis of traditional and coiled fiducials implanted during EUS for pancreatic cancer patients receiving stereotactic body radiation therapy. , 2012, Gastrointestinal endoscopy.

[24]  P. Murawa,et al.  Erlotinib Plus Gemcitabine Compared With Gemcitabine Alone in Patients With Advanced Pancreatic Cancer: A Phase III Trial of the National Cancer Institute of Canada Clinical Trials Group , 2023, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[25]  E. Feuer,et al.  SEER Cancer Statistics Review, 1975-2003 , 2006 .

[26]  J. Vauthey,et al.  AHPBA/SSO/SSAT Consensus Conference on Resectable and Borderline Resectable Pancreatic Cancer: Rationale and Overview of the Conference , 2009, Annals of Surgical Oncology.

[27]  Alison P. Klein,et al.  DPC4 gene status of the primary carcinoma correlates with patterns of failure in patients with pancreatic cancer. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[28]  K. Hess,et al.  Phase 2 trial of oxaliplatin plus capecitabine (XELOX) as second‐line therapy for patients with advanced pancreatic cancer , 2008, Cancer.

[29]  B. Lau,et al.  Importance of Age of Onset in Pancreatic Cancer Kindreds , 2010, Journal of the National Cancer Institute.

[30]  M. Makary,et al.  Is it necessary to follow patients after resection of a benign pancreatic intraductal papillary mucinous neoplasm? , 2013, Journal of the American College of Surgeons.

[31]  R. Schilsky,et al.  Gemcitabine plus bevacizumab compared with gemcitabine plus placebo in patients with advanced pancreatic cancer: phase III trial of the Cancer and Leukemia Group B (CALGB 80303). , 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[32]  M. Robson,et al.  An emerging entity: pancreatic adenocarcinoma associated with a known BRCA mutation: clinical descriptors, treatment implications, and future directions. , 2011, The oncologist.

[33]  J. Cameron,et al.  Pulmonary Resection for Isolated Pancreatic Adenocarcinoma Metastasis: an Analysis of Outcomes and Survival , 2011, Journal of Gastrointestinal Surgery.

[34]  Wei Zheng,et al.  Anthropometric measures, body mass index, and pancreatic cancer: a pooled analysis from the Pancreatic Cancer Cohort Consortium (PanScan). , 2010, Archives of internal medicine.

[35]  S. Hanash,et al.  A Compendium of Potential Biomarkers of Pancreatic Cancer , 2009, PLoS medicine.

[36]  Kathleen M Murphy,et al.  Evaluation of candidate genes MAP2K4, MADH4, ACVR1B, and BRCA2 in familial pancreatic cancer: deleterious BRCA2 mutations in 17%. , 2002, Cancer research.

[37]  Helen Hickey,et al.  A randomized trial of chemoradiotherapy and chemotherapy after resection of pancreatic cancer. , 2004, The New England journal of medicine.

[38]  Carlos Cuevas,et al.  Enzymatic targeting of the stroma ablates physical barriers to treatment of pancreatic ductal adenocarcinoma. , 2012, Cancer cell.

[39]  Y. Kuo,et al.  The effect of depression on stage at diagnosis, treatment, and survival in pancreatic adenocarcinoma. , 2012, Surgery.

[40]  A. Koong,et al.  18Fluorodeoxyglucose PET is prognostic of progression-free and overall survival in locally advanced pancreas cancer treated with stereotactic radiotherapy. , 2010, International journal of radiation oncology, biology, physics.

[41]  B. Sipos,et al.  Pancreatic fibrosis associated with age and ductal papillary hyperplasia , 2005, Virchows Archiv.

[42]  A J Krush,et al.  Increased risk of cancer in the Peutz-Jeghers syndrome. , 1987, The New England journal of medicine.

[43]  K. Campbell,et al.  Clinical importance of precursor lesions in the pancreas. , 2007, Journal of hepato-biliary-pancreatic surgery.

[44]  L. Pickle,et al.  Life-style risk factors for pancreatic cancer in Louisiana: a case-control study. , 1988, American journal of epidemiology.

[45]  Laura M. Heiser,et al.  A central role for RAF→MEK→ERK signaling in the genesis of pancreatic ductal adenocarcinoma. , 2012, Cancer discovery.

[46]  D. V. Von Hoff,et al.  Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer: a randomized trial. , 1997, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[47]  R. Hruban,et al.  Gastrointestinal Cancer : Targets and Therapy Precursors to invasive pancreatic cancer , 2012 .

[48]  J. Forgensen.  Resected adenocarcinoma of the pancreas--616 patients: results, outcomes, and prognostic indicators. , 2001, Journal of gastrointestinal surgery : official journal of the Society for Surgery of the Alimentary Tract.

[49]  Geoffrey S. Tobias,et al.  Family history of cancer and risk of pancreatic cancer: A pooled analysis from the Pancreatic Cancer Cohort Consortium (PanScan) , 2010, International journal of cancer.

[50]  C. Thompson,et al.  Glutamine addiction: a new therapeutic target in cancer. , 2010, Trends in biochemical sciences.

[51]  J. Berlin,et al.  Full-dose gemcitabine with concurrent radiation therapy in patients with nonmetastatic pancreatic cancer: a multicenter phase II trial. , 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[52]  K. T. Steigelman.  Tumors of the pancreas. , 1951, The Journal of the American Osteopathic Association.

[53]  A. Moser,et al.  A phase I/II study of a MUC1 peptide pulsed autologous dendritic cell vaccine as adjuvant therapy in patients with resected pancreatic and biliary tumors. , 2008, Cancer therapy.

[54]  G. Parmigiani,et al.  Genetic mutations associated with cigarette smoking in pancreatic cancer. , 2009, Cancer research.

[55]  T. Therneau,et al.  Number of Lymph Nodes Evaluated: Prognostic Value in Pancreatic Adenocarcinoma , 2012, Journal of Gastrointestinal Surgery.

[56]  Christopher H. Crane,et al.  Pancreaticoduodenectomy with vascular resection: margin status and survival duration , 2004, Journal of Gastrointestinal Surgery.

[57]  Alona Muzikansky,et al.  Capecitabine plus erlotinib in gemcitabine-refractory advanced pancreatic cancer. , 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[58]  Giovanni Parmigiani,et al.  SMAD4 Gene Mutations Are Associated with Poor Prognosis in Pancreatic Cancer , 2009, Clinical Cancer Research.

[59]  J. Jeekel,et al.  Adjuvant radiotherapy and 5-fluorouracil after curative resection of cancer of the pancreas and periampullary region: phase III trial of the EORTC gastrointestinal tract cancer cooperative group. , 1999, Annals of surgery.

[60]  Manuel Hidalgo,et al.  Personalizing Cancer Treatment in the Age of Global Genomic Analyses: PALB2 Gene Mutations and the Response to DNA Damaging Agents in Pancreatic Cancer , 2010, Molecular Cancer Therapeutics.

[61]  H. Friess,et al.  Adjuvant chemotherapy with fluorouracil plus folinic acid vs gemcitabine following pancreatic cancer resection: a randomized controlled trial. , 2010, JAMA.

[62]  R. Abrams,et al.  Fluorouracil vs gemcitabine chemotherapy before and after fluorouracil-based chemoradiation following resection of pancreatic adenocarcinoma: a randomized controlled trial. , 2008, JAMA.

[63]  J. Neoptolemos,et al.  Meta-analyses of chemotherapy for locally advanced and metastatic pancreatic cancer: results of secondary end points analyses , 2008, British Journal of Cancer.

[64]  Wei Zheng,et al.  A genome-wide association study identifies pancreatic cancer susceptibility loci on chromosomes 13q22.1, 1q32.1 and 5p15.33 , 2010, Nature Genetics.

[65]  Drew A. Torigian,et al.  CD40 Agonists Alter Tumor Stroma and Show Efficacy Against Pancreatic Carcinoma in Mice and Humans , 2011, Science.

[66]  M. Lerch,et al.  Cigarette smoking as a risk factor for pancreatic cancer in patients with hereditary pancreatitis. , 2001, JAMA.

[67]  G. Schwartz,et al.  A phase I study of erlotinib in combination with gemcitabine and radiation in locally advanced, non-operable pancreatic adenocarcinoma. , 2008, Annals of oncology : official journal of the European Society for Medical Oncology.

[68]  A. Koong,et al.  A dosimetric model of duodenal toxicity after stereotactic body radiotherapy for pancreatic cancer. , 2010, International journal of radiation oncology, biology, physics.

[69]  David Cella,et al.  Gemcitabine alone versus gemcitabine plus radiotherapy in patients with locally advanced pancreatic cancer: an Eastern Cooperative Oncology Group trial. , 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[70]  Mariza de Andrade,et al.  Probability of pancreatic cancer following diabetes: a population-based study. , 2005, Gastroenterology.

[71]  Douglas B. Evans,et al.  Cancer-associated stromal fibroblasts promote pancreatic tumor progression. , 2008, Cancer research.

[72]  David Allard,et al.  Inhibition of Hedgehog Signaling Enhances Delivery of Chemotherapy in a Mouse Model of Pancreatic Cancer , 2009, Science.

[73]  A. Chang,et al.  Capecitabine and radiation therapy preceded and followed by combination chemotherapy in advanced pancreatic cancer. , 2005, International journal of radiation oncology, biology, physics.

[74]  C. Langmead,et al.  ANGIOPOIETIN-2, A REGULATOR OF VASCULAR PERMEABILITY IN INFLAMMATION IS ELEVATED IN SEVERE ACUTE PANCREATITIS AND IS ASSOCIATED WITH SYSTEMIC ORGAN FAILURE , 2008 .

[75]  D. Stocken,et al.  A Randomized Phase 2 Trial of Neoadjuvant Chemotherapy in Resectable Pancreatic Cancer: Gemcitabine Alone Versus Gemcitabine Combined with Cisplatin , 2007, Annals of Surgical Oncology.

[76]  R. Goldberg,et al.  Randomized phase II study of gemcitabine administered at a fixed dose rate or in combination with cisplatin, docetaxel, or irinotecan in patients with metastatic pancreatic cancer: CALGB 89904. , 2009, Journal of Clinical Oncology.

[77]  Steven Gallinger,et al.  Germline BRCA2 6174delT mutations in Ashkenazi Jewish pancreatic cancer patients , 1997, Nature Genetics.

[78]  A. Rustgi,et al.  The genetics of hereditary colon cancer. , 2007, Genes & development.

[79]  N. Dubrawsky.  Cancer statistics , 1989, CA: a cancer journal for clinicians.

[80]  A. Maitra,et al.  Gemcitabine plus nab-paclitaxel is an active regimen in patients with advanced pancreatic cancer: a phase I/II trial. , 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[81]  B. McKay,et al.  Enhanced cytotoxicity of PARP inhibition in mantle cell lymphoma harbouring mutations in both ATM and p53 , 2012, EMBO molecular medicine.

[82]  Priya R Bhosale,et al.  Imaging of pancreatic adenocarcinoma: update on staging/resectability. , 2012, Radiologic clinics of North America.

[83]  F. Bosman,et al.  WHO Classification of Tumours of the Digestive System , 2010 .

[84]  J. Stockman,et al.  Everolimus for Subependymal Giant-Cell Astrocytomas in Tuberous Sclerosis , 2012 .

[85]  R. Hruban,et al.  In vivo Therapeutic Responses Contingent on Fanconi Anemia/BRCA2 Status of the Tumor , 2005, Clinical Cancer Research.

[86]  Eileen M O'Reilly,et al.  Randomized phase III study of exatecan and gemcitabine compared with gemcitabine alone in untreated advanced pancreatic cancer. , 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[87]  M. Schäfer,et al.  Prospective phase II trial of neoadjuvant chemotherapy with gemcitabine and cisplatin for resectable adenocarcinoma of the pancreatic head. , 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[88]  M. Fung,et al.  [Chemotherapy for advanced or metastatic pancreatic cancer: analysis of 43 randomized trials in 3 decades (1974-2002)]. , 2003, Gan to kagaku ryoho. Cancer & chemotherapy.

[89]  M. Regueiro.  Analysis of the Gene Coding for the BRCA2-Interacting Protein PALB2 in Familial and Sporadic Pancreatic Cancer , 2009 .

[90]  A. Scarpa,et al.  Growth delay of human pancreatic cancer cells by methylase inhibitor 5-aza-2′-deoxycytidine treatment is associated with activation of the interferon signalling pathway , 2005, Oncogene.

[91]  Christopher G Willett,et al.  Failure to adhere to protocol specified radiation therapy guidelines was associated with decreased survival in RTOG 9704--a phase III trial of adjuvant chemotherapy and chemoradiotherapy for patients with resected adenocarcinoma of the pancreas. , 2012, International journal of radiation oncology, biology, physics.

[92]  J. Cameron,et al.  Comparison of conventional and 3-dimensional computed tomography against histopathologic examination in determining pancreatic adenocarcinoma tumor size: implications for radiation therapy planning. , 2012, Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology.

[93]  M. Kendrick,et al.  Total laparoscopic pancreaticoduodenectomy: feasibility and outcome in an early experience. , 2010, Archives of surgery.

[94]  E. Touboul,et al.  Impact of chemoradiotherapy after disease control with chemotherapy in locally advanced pancreatic adenocarcinoma in GERCOR phase II and III studies. , 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[95]  P. Boyle,et al.  Reported family aggregation of pancreatic cancer within a population-based case-control study in the francophone community in Montreal, Canada , 1991, International journal of pancreatology : official journal of the International Association of Pancreatology.

[96]  M. Hidalgo,et al.  Randomized phase III study of weekly nab-paclitaxel plus gemcitabine versus gemcitabine alone in patients with metastatic adenocarcinoma of the pancreas (MPACT). , 2013 .

[97]  V. Sondak,et al.  Management of familial melanoma and nonmelanoma skin cancer syndromes. , 2009, Surgical oncology clinics of North America.

[98]  A. Kimmelman,et al.  A critical role for autophagy in pancreatic cancer , 2011, Autophagy.

[99]  Alison P. Klein,et al.  Exomic Sequencing Identifies PALB2 as a Pancreatic Cancer Susceptibility Gene , 2009, Science.

[100]  B. Erickson,et al.  Weekly paclitaxel, gemcitabine, and external irradiation followed by randomized farnesyl transferase inhibitor R115777 for locally advanced pancreatic cancer , 2012, OncoTargets and therapy.

[101]  M. Kamiyama,et al.  Absence of germline BRCA1 mutations in familial pancreatic cancer patients , 2009, Cancer biology & therapy.

[102]  N. Scarmeas,et al.  CA 19-9 levels predict results of staging laparoscopy in pancreatic cancer , 2005, Journal of Gastrointestinal Surgery.

[103]  J. Cameron,et al.  Multifocal Neoplastic Precursor Lesions Associated With Lobular Atrophy of the Pancreas in Patients Having a Strong Family History of Pancreatic Cancer , 2006, The American journal of surgical pathology.

[104]  J. Hainsworth,et al.  Randomized phase II comparison of dose-intense gemcitabine: thirty-minute infusion and fixed dose rate infusion in patients with pancreatic adenocarcinoma. , 2003, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[105]  A. Maitra,et al.  Conceptual Framework for Cutting the Pancreatic Cancer Fuel Supply , 2012, Clinical Cancer Research.

[106]  P Boffetta,et al.  Alcohol consumption and pancreatic cancer: a pooled analysis in the International Pancreatic Cancer Case-Control Consortium (PanC4). , 2012, Annals of oncology : official journal of the European Society for Medical Oncology.

[107]  M. Gorry,et al.  Hereditary pancreatitis is caused by a mutation in the cationic trypsinogen gene , 1996, Nature Genetics.

[108]  J. Cameron,et al.  Surgical management of solid-pseudopapillary neoplasms of the pancreas (Franz or Hamoudi tumors): a large single-institutional series. , 2009, Journal of the American College of Surgeons.

[109]  Steven P. Cohen,et al.  Assessment of celiac plexus block and neurolysis outcomes and technique in the management of refractory visceral cancer pain. , 2010, Pain medicine.

[110]  C. Moskaluk,et al.  Novel germline p16INK4 allele (Asp145Cys) in a family with multiple pancreatic carcinomas , 1998 .

[111]  J. Quivey,et al.  A phase II study of fixed-dose rate gemcitabine plus low-dose cisplatin followed by consolidative chemoradiation for locally advanced pancreatic cancer. , 2007, International journal of radiation oncology, biology, physics.

[112]  R. Labianca,et al.  Gemcitabine in combination with oxaliplatin compared with gemcitabine alone in locally advanced or metastatic pancreatic cancer: results of a GERCOR and GISCAD phase III trial. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[113]  C. Compton,et al.  Resection margins in carcinoma of the head of the pancreas. Implications for radiation therapy. , 1993, Annals of surgery.

[114]  R. Hruban,et al.  Correction: International Cancer of the Pancreas Screening (CAPS) Consortium summit on the management of patients with increased risk for familial pancreatic cancer (Gut (2013) 62, (339-347)) , 2014 .

[115]  B. Yan,et al.  Neurolytic Celiac Plexus Block for Pain Control in Unresectable Pancreatic Cancer , 2007, The American Journal of Gastroenterology.

[116]  Fuqiang Wen,et al.  Diagnostic value of microRNA for pancreatic cancer: a meta-analysis , 2012, Archives of medical science : AMS.

[117]  S. Chanock,et al.  ABO blood group and the risk of pancreatic cancer. , 2009, Journal of the National Cancer Institute.

[118]  Eric D Wieben,et al.  Prevalence of CDKN2A mutations in pancreatic cancer patients: implications for genetic counseling , 2011, European Journal of Human Genetics.

[119]  C. Iacobuzio-Donahue,et al.  Peritumoral fibroblast SPARC expression and patient outcome with resectable pancreatic adenocarcinoma. , 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[120]  M. Choti,et al.  Peri‐operative mortality and long‐term survival after total pancreatectomy for pancreatic adenocarcinoma: A population‐based perspective , 2009, Journal of surgical oncology.

[121]  R. Wahl,et al.  The promise and pitfalls of positron emission tomography and single-photon emission computed tomography molecular imaging-guided radiation therapy. , 2011, Seminars in radiation oncology.

[122]  G. Eslick,et al.  A Systematic Review and Meta-analysis of Survival and Surgical Outcomes Following Neoadjuvant Chemoradiotherapy for Pancreatic Cancer , 2011, Journal of Gastrointestinal Surgery.

[123]  Peter Neuhaus,et al.  Adjuvant chemotherapy with gemcitabine vs observation in patients undergoing curative-intent resection of pancreatic cancer: a randomized controlled trial. , 2007, JAMA.

[124]  Mariza de Andrade,et al.  The Prevalence of BRCA2 Mutations in Familial Pancreatic Cancer , 2007, Cancer Epidemiology Biomarkers & Prevention.

[125]  Olfert Landt,et al.  Mutations in the gene encoding the serine protease inhibitor, Kazal type 1 are associated with chronic pancreatitis , 2000, Nature Genetics.

[126]  R. Armitage,et al.  Screening for Depression, Sleep-Related Disturbances, and Anxiety in Patients with Adenocarcinoma of the Pancreas: A Preliminary Study , 2012, TheScientificWorldJournal.

[127]  Patrick Maisonneuve,et al.  Epidemiology of Pancreatic Cancer: An Update , 2010, Digestive Diseases.

[128]  R. Abrams,et al.  Review and Commentary on the Role of Radiation Therapy in the Adjuvant Management of Pancreatic Cancer , 2010, American journal of clinical oncology.

[129]  G. Ying,et al.  Familial risk of pancreatic cancer. , 2001, Journal of the National Cancer Institute.

[130]  E. Paulson,et al.  Staging of pancreatic cancer before and after neoadjuvant chemoradiation , 2001, Journal of Gastrointestinal Surgery.

[131]  W. Scheithauer,et al.  Phase III randomized comparison of gemcitabine versus gemcitabine plus capecitabine in patients with advanced pancreatic cancer. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[132]  Kristy K Brock,et al.  Accuracy of daily image guidance for hypofractionated liver radiotherapy with active breathing control. , 2005, International journal of radiation oncology, biology, physics.

[133]  K. Lillemoe,et al.  A Lethally Irradiated Allogeneic Granulocyte-Macrophage Colony Stimulating Factor-Secreting Tumor Vaccine for Pancreatic Adenocarcinoma: A Phase II Trial of Safety, Efficacy, and Immune Activation , 2011, Annals of surgery.

[134]  Eric C Ford,et al.  Use of respiratory-correlated four-dimensional computed tomography to determine acceptable treatment margins for locally advanced pancreatic adenocarcinoma. , 2010, International journal of radiation oncology, biology, physics.

[135]  Derek S. Chan,et al.  Hyaluronan impairs vascular function and drug delivery in a mouse model of pancreatic cancer , 2012, Gut.

[136]  A. Rashid,et al.  Histopathological identification of colon cancer with microsatellite instability. , 2001, The American journal of pathology.

[137]  J. Donohue,et al.  Adjuvant radiotherapy and chemotherapy for pancreatic carcinoma: the Mayo Clinic experience (1975-2005). , 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[138]  K. Kinzler,et al.  Genetically Defined Subsets of Human Pancreatic Cancer Show Unique In Vitro Chemosensitivity , 2012, Clinical Cancer Research.

[139]  W. Foulkes,et al.  Analysis of the gene coding for the BRCA2-interacting protein PALB2 in familial and sporadic pancreatic cancer. , 2009, Gastroenterology.

[140]  Catrin Tudur Smith,et al.  Meta-analyses of chemotherapy for locally advanced and metastatic pancreatic cancer. , 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[141]  P. Catalano,et al.  Phase III, randomized study of gemcitabine and oxaliplatin versus gemcitabine (fixed-dose rate infusion) compared with gemcitabine (30-minute infusion) in patients with pancreatic carcinoma E6201: a trial of the Eastern Cooperative Oncology Group. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[142]  M. Makary,et al.  Laparoscopic Distal Pancreatectomy Is Associated With Significantly Less Overall Morbidity Compared to the Open Technique: A Systematic Review and Meta-Analysis , 2012, Annals of surgery.

[143]  M. Choti,et al.  Early Mortality Risk Score: Identification of Poor Outcomes Following Upfront Surgery for Resectable Pancreatic Cancer , 2012, Journal of Gastrointestinal Surgery.

[144]  M M Grajower,et al.  Familial pancreatic cancer. , 1983, Annals of internal medicine.

[145]  T. Gress,et al.  Pancreatic Intraepithelial Neoplasia Revisited and Updated , 2008, Pancreatology.

[146]  M. Kanda,et al.  Mutant TP53 in duodenal samples of pancreatic juice from patients with pancreatic cancer or high-grade dysplasia. , 2013, Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association.

[147]  J. Cameron,et al.  STK11/LKB1 Peutz-Jeghers gene inactivation in intraductal papillary-mucinous neoplasms of the pancreas. , 2001, The American journal of pathology.

[148]  K. Horton,et al.  Prevalence of unsuspected pancreatic cysts on MDCT. , 2008, AJR. American journal of roentgenology.

[149]  J. Struewing,et al.  Prospective risk of cancer in CDKN2A germline mutation carriers , 2004, Journal of Medical Genetics.

[150]  E. Fishman,et al.  Screening for early pancreatic neoplasia in high-risk individuals: a prospective controlled study. , 2006, Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association.

[151]  O. Yokosuka,et al.  Phase II study of oral S-1 and concurrent radiotherapy in patients with unresectable locally advanced pancreatic cancer. , 2011, International journal of radiation oncology, biology, physics.

[152]  Zhe Zhang,et al.  Frequent detection of pancreatic lesions in asymptomatic high-risk individuals. , 2012, Gastroenterology.

[153]  K. Hara,et al.  Clinical impact of radiotherapy for locally advanced pancreatic cancer , 2009, Journal of Gastroenterology.

[154]  C. Moskaluk,et al.  Germline BRCA2 gene mutations in patients with apparently sporadic pancreatic carcinomas. , 1996, Cancer research.

[155]  A. Koong,et al.  Stereotactic body radiation therapy for gastrointestinal malignancies. , 2011, Frontiers of radiation therapy and oncology.

[156]  K. Campbell,et al.  Predicting resectability of periampullary cancer with three-dimensional computed tomography , 2004, Journal of Gastrointestinal Surgery.

[157]  Ira Pastan,et al.  Mesothelin: a new target for immunotherapy. , 2004, Clinical cancer research : an official journal of the American Association for Cancer Research.

[158]  Douglas F Easton,et al.  Cancer Incidence in BRCA1 mutation carriers. , 2002, Journal of the National Cancer Institute.

[159]  E. Dimagno,et al.  Hereditary pancreatitis and the risk of pancreatic cancer. International Hereditary Pancreatitis Study Group. , 1997, Journal of the National Cancer Institute.

[160]  G. Y. Wong,et al.  Effect of neurolytic celiac plexus block on pain relief, quality of life, and survival in patients with unresectable pancreatic cancer: a randomized controlled trial. , 2004, JAMA.

[161]  R. Schmid,et al.  Pancreatic cancer and depression: myth and truth , 2010, BMC Cancer.

[162]  Marc Liesa,et al.  Pancreatic cancers require autophagy for tumor growth. , 2011, Genes & development.

[163]  Thomas J. Smith,et al.  Randomized clinical trial of an implantable drug delivery system compared with comprehensive medical management for refractory cancer pain: impact on pain, drug-related toxicity, and survival. , 2002, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[164]  A. Jimeno,et al.  Genome-wide profiling at methylated promoters in pancreatic adenocarcinoma , 2008, Cancer biology & therapy.

[165]  A. Halpern,et al.  Heterogeneity of risk for melanoma and pancreatic and digestive malignancies , 2004, Cancer.

[166]  M. Kendrick,et al.  Major venous resection during total laparoscopic pancreaticoduodenectomy. , 2011, HPB : the official journal of the International Hepato Pancreato Biliary Association.

[167]  D. Rattner,et al.  Impact of laparoscopic staging in the treatment of pancreatic cancer. , 2000, Archives of surgery.

[168]  M. Milella,et al.  FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer. , 2011, The New England journal of medicine.

[169]  A. Adai,et al.  miRNA Biomarkers in Cyst Fluid Augment the Diagnosis and Management of Pancreatic Cysts , 2012, Clinical Cancer Research.

[170]  J. Jeekel,et al.  Serum CA19-9 determination in the management of pancreatic cancer. , 1996, Hepato-gastroenterology.

[171]  L. Case,et al.  Phase II Trial of Induction Gemcitabine/CPT-11 Followed by a Twice-Weekly Infusion of Gemcitabine and Concurrent External Beam Radiation for the Treatment of Locally Advanced Pancreatic Cancer , 2005, American journal of clinical oncology.

[172]  J. Birkmeyer,et al.  Hospital volume and surgical mortality in the United States. , 2002, The New England journal of medicine.

[173]  Douglas B. Evans,et al.  Induction chemotherapy selects patients with locally advanced, unresectable pancreatic cancer for optimal benefit from consolidative chemoradiation therapy , 2007, Cancer.

[174]  K. Vineberg,et al.  Potential for dose-escalation and reduction of risk in pancreatic cancer using IMRT optimization with lexicographic ordering and gEUD-based cost functions. , 2007, Medical physics.

[175]  J. Cameron,et al.  Mesothelin is overexpressed in the vast majority of ductal adenocarcinomas of the pancreas: identification of a new pancreatic cancer marker by serial analysis of gene expression (SAGE). , 2001, Clinical cancer research : an official journal of the American Association for Cancer Research.

[176]  J. Wargo,et al.  Management of pancreatic serous cystadenomas. , 2009, Advances in surgery.

[177]  J. Donohue,et al.  Gastrointestinal stromal tumour of the duodenum: single institution experience. , 2012, HPB : the official journal of the International Hepato Pancreato Biliary Association.

[178]  D. Whitcomb.  Genetics of alcoholic and nonalcoholic pancreatitis , 2012, Current opinion in gastroenterology.

[179]  J. Cameron,et al.  Diagnosing Pancreatic Cancer Using Methylation Specific PCR Analysis , 2003, Cancer biology & therapy.

[180]  M. Yashiro,et al.  Prognostic value of microsatellite instability in resectable pancreatic cancer. , 2002, Clinical cancer research : an official journal of the American Association for Cancer Research.

[181]  D. V. Von Hoff,et al.  A phase III trial of pemetrexed plus gemcitabine versus gemcitabine in patients with unresectable or metastatic pancreatic cancer. , 2005, Annals of oncology : official journal of the European Society for Medical Oncology.

[182]  J. Cameron,et al.  Adjuvant Chemoradiation for Pancreatic Adenocarcinoma: The Johns Hopkins Hospital—Mayo Clinic Collaborative Study , 2010, Annals of Surgical Oncology.

[183]  K. Strauch,et al.  PALB2 mutations in European familial pancreatic cancer families , 2010, Clinical genetics.

[184]  A. Stout,et al.  Atlas of Tumor Pathology , 1954, American journal of clinical pathology.

[185]  Jeffrey E. Lee,et al.  Phase II trial of cetuximab, gemcitabine, and oxaliplatin followed by chemoradiation with cetuximab for locally advanced (T4) pancreatic adenocarcinoma: correlation of Smad4(Dpc4) immunostaining with pattern of disease progression. , 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[186]  M. Kalser,et al.  Further evidence of effective adjuvant combined radiation and chemotherapy following curative resection of pancreatic cancer , 1987, Cancer.

[187]  S. Ellenberg,et al.  Pancreatic cancer. Adjuvant combined radiation and chemotherapy following curative resection. , 1985, Archives of surgery.

[188]  A. Maitra,et al.  Recurrent GNAS Mutations Define an Unexpected Pathway for Pancreatic Cyst Development , 2011, Science Translational Medicine.

[189]  J. Kleeff,et al.  Tumor microenvironment and progression of pancreatic cancer. , 2010, Experimental oncology.

[190]  R. Labianca,et al.  Meta-analysis of randomized trials: evaluation of benefit from gemcitabine-based combination chemotherapy applied in advanced pancreatic cancer , 2008, BMC Cancer.

[191]  D. Whitcomb,et al.  Genetics of Pancreatitis: An Update for Clinicians and Genetic Counselors , 2012, Current Gastroenterology Reports.

[192]  Paul Fockens,et al.  International Cancer of the Pancreas Screening (CAPS) Consortium summit on the management of patients with increased risk for familial pancreatic cancer , 2012, Gut.

[193]  J. Cameron,et al.  Histopathologic Basis for the Favorable Survival after Resection of Intraductal Papillary Mucinous Neoplasm-Associated Invasive Adenocarcinoma of the Pancreas , 2010, Annals of surgery.

[194]  R. Labianca,et al.  Randomized phase III trial of gemcitabine plus cisplatin compared with single-agent gemcitabine as first-line treatment of patients with advanced pancreatic cancer: the GIP-1 study. , 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[195]  R. Hruban,et al.  Sensitive and quantitative detection of KRAS2 gene mutations in pancreatic duct juice differentiates patients with pancreatic cancer from chronic pancreatitis, potential for early detection , 2008, Cancer biology & therapy.

[196]  A. Jemal,et al.  Cancer statistics, 2013 , 2013, CA: a cancer journal for clinicians.

[197]  M. Choti,et al.  Genetic, immunohistochemical, and clinical features of medullary carcinoma of the pancreas: A newly described and characterized entity. , 2000, The American journal of pathology.

[198]  Yuchen Jiao,et al.  ATM mutations in patients with hereditary pancreatic cancer. , 2012, Cancer discovery.

[199]  K. Campbell,et al.  Evaluating the Impact of a Single-Day Multidisciplinary Clinic on the Management of Pancreatic Cancer , 2008, Annals of Surgical Oncology.

[200]  B. Dörken,et al.  Best supportive care (BSC) versus oxaliplatin, folinic acid and 5-fluorouracil (OFF) plus BSC in patients for second-line advanced pancreatic cancer: a phase III-study from the German CONKO-study group. , 2011, European journal of cancer.

[201]  A. Maitra,et al.  Whole-exome sequencing of neoplastic cysts of the pancreas reveals recurrent mutations in components of ubiquitin-dependent pathways , 2011, Proceedings of the National Academy of Sciences.

[202]  C. Moskaluk,et al.  Novel germline p16(INK4) allele (Asp145Cys) in a family with multiple pancreatic carcinomas. Mutations in brief no. 148. Online. , 1998, Human mutation.

[203]  B. B. Weitner,et al.  Phase II trial of full-dose gemcitabine and bevacizumab in combination with attenuated three-dimensional conformal radiotherapy in patients with localized pancreatic cancer. , 2011, International journal of radiation oncology, biology, physics.

[204]  J. Stockman,et al.  Risk of Pancreatic Cancer in Families With Lynch Syndrome , 2011 .

[205]  Jeffrey E. Lee,et al.  Effect of Neoadjuvant Chemoradiation and Surgical Technique on Recurrence of Localized Pancreatic Cancer , 2011, Journal of Gastrointestinal Surgery.

[206]  E. Kuipers,et al.  Pancreatic cancer risk in Peutz-Jeghers syndrome patients: a large cohort study and implications for surveillance , 2012, Journal of Medical Genetics.

[207]  J. Cameron,et al.  Resected pancreatic adenosquamous carcinoma: clinicopathologic review and evaluation of adjuvant chemotherapy and radiation in 38 patients. , 2010, Human pathology.

[208]  Yingze Zhang,et al.  A gene for hereditary pancreatitis maps to chromosome 7q35. , 1996, Gastroenterology.

[209]  L. Diaz,et al.  A multicenter analysis of GTX chemotherapy in patients with locally advanced and metastatic pancreatic adenocarcinoma , 2011, Cancer Chemotherapy and Pharmacology.

[210]  Y. Genyk,et al.  Extended pancreatectomy with resection of the celiac axis: the modified Appleby operation. , 2006, American journal of surgery.

[211]  K. Campbell,et al.  Resected periampullary adenocarcinoma: 5-year survivors and their 6- to 10-year follow-up. , 2006, Surgery.

[212]  P. Gleeson,et al.  Macropinocytosis: an endocytic pathway for internalising large gulps , 2011, Immunology and cell biology.

[213]  J. Cameron,et al.  Elevated Cancer Mortality in the Relatives of Patients with Pancreatic Cancer , 2009, Cancer Epidemiology, Biomarkers & Prevention.

[214]  A. Roy,et al.  EUS-guided pancreatic fluid aspiration for DNA analysis of KRAS and GNAS mutations for the evaluation of pancreatic cystic neoplasia: a pilot study. , 2013, Gastrointestinal endoscopy.

[215]  Michael A. Choti,et al.  1423 pancreaticoduodenectomies for pancreatic cancer: A single-institution experience , 2006, Journal of Gastrointestinal Surgery.

[216]  M. Kanda,et al.  Mutant GNAS detected in duodenal collections of secretin-stimulated pancreatic juice indicates the presence or emergence of pancreatic cysts , 2012, Gut.

[217]  E. Touboul,et al.  Concomitant administration of weekly oxaliplatin, fluorouracil continuous infusion, and radiotherapy after 2 months of gemcitabine and oxaliplatin induction in patients with locally advanced pancreatic cancer: a Groupe Coordinateur Multidisciplinaire en Oncologie phase II study. , 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[218]  C. Férec,et al.  The hereditary pancreatitis gene maps to long arm of chromosome 7. , 1996, Human molecular genetics.

[219]  W. Miller,et al.  Irinotecan plus gemcitabine results in no survival advantage compared with gemcitabine monotherapy in patients with locally advanced or metastatic pancreatic cancer despite increased tumor response rate. , 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[220]  J. Stockman,et al.  Everolimus for Advanced Pancreatic Neuroendocrine Tumors , 2012 .

[221]  Laura H. Tang,et al.  BRCA germline mutations in Jewish patients with pancreatic adenocarcinoma. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[222]  R. Abrams,et al.  Multicenter phase II trial of adjuvant therapy for resected pancreatic cancer using cisplatin, 5-fluorouracil, and interferon-alfa-2b-based chemoradiation: ACOSOG Trial Z05031. , 2011, Annals of oncology : official journal of the European Society for Medical Oncology.

[223]  G. Parmigiani,et al.  Core Signaling Pathways in Human Pancreatic Cancers Revealed by Global Genomic Analyses , 2008, Science.

[224]  W. Kaelin,et al.  Q&A: Cancer: Clues from cell metabolism , 2010, Nature.

[225]  J. Cameron,et al.  A tolerability and pharmacokinetic study of adjuvant erlotinib and capecitabine with concurrent radiation in resected pancreatic cancer. , 2010, Translational oncology.

[226]  Jeffrey E. Lee,et al.  Preoperative gemcitabine-based chemoradiation for patients with resectable adenocarcinoma of the pancreatic head. , 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[227]  M. Brennan,et al.  Laparoscopy for staging abdominal malignancies. , 2000, Advances in surgery.

[228]  T. Riall,et al.  415 patients with adenosquamous carcinoma of the pancreas: a population-based analysis of prognosis and survival. , 2011, The Journal of surgical research.

[229]  N. Girard,et al.  Preoperative chemoradiation in potentially resectable pancreatic adenocarcinoma: feasibility, treatment effect evaluation and prognostic factors, analysis of the SFRO-FFCD 9704 trial and literature review. , 2009, Annals of oncology : official journal of the European Society for Medical Oncology.

[230]  E. Kuipers,et al.  High Cancer Risk in Peutz–Jeghers Syndrome: A Systematic Review and Surveillance Recommendations , 2010, The American Journal of Gastroenterology.

[231]  H. Einsele,et al.  Randomized phase III trial of gemcitabine plus cisplatin compared with gemcitabine alone in advanced pancreatic cancer. , 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[232]  W. Curran,et al.  Phase II study of bevacizumab with concurrent capecitabine and radiation followed by maintenance gemcitabine and bevacizumab for locally advanced pancreatic cancer: Radiation Therapy Oncology Group RTOG 0411. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[233]  Alexander D. MacKerell,et al.  Small‐Molecule Inhibitors of the ERK Signaling Pathway: Towards Novel Anticancer Therapeutics , 2011, ChemMedChem.

[234]  M. Woodward,et al.  Type-II diabetes and pancreatic cancer: a meta-analysis of 36 studies , 2005, British Journal of Cancer.

[235]  T. Price,et al.  Familial pancreatic cancer in south Louisiana. , 1996, Cancer nursing.

[236]  R. McLendon,et al.  Altered Telomeres in Tumors with ATRX and DAXX Mutations , 2011, Science.

[237]  Tibor Schuster,et al.  Preoperative/Neoadjuvant Therapy in Pancreatic Cancer: A Systematic Review and Meta-analysis of Response and Resection Percentages , 2010, PLoS medicine.

[238]  A. Miller,et al.  Cigarette smoking and pancreatic cancer: an analysis from the International Pancreatic Cancer Case-Control Consortium (Panc4). , 2012, Annals of oncology : official journal of the European Society for Medical Oncology.

[239]  K. Lillemoe,et al.  Almost All Infiltrating Colloid Carcinomas of the Pancreas and Periampullary Region Arise From In Situ Papillary Neoplasms: A Study of 39 Cases , 2002, The American journal of surgical pathology.

[240]  K. Lillemoe,et al.  Resected adenocarcinoma of the pancreas— 616 patients: Results, outcomes, and prognostic indicators , 2000, Journal of Gastrointestinal Surgery.

[241]  Jeffrey E. Lee,et al.  Borderline resectable pancreatic cancer: the importance of this emerging stage of disease. , 2008, Journal of the American College of Surgeons.

[242]  E. Nakakura,et al.  Pancreatic Adenocarcinoma, version 2.2012: featured updates to the NCCN Guidelines. , 2012, Journal of the National Comprehensive Cancer Network : JNCCN.

[243]  K. Campbell,et al.  Resected periampullary adenocarcinoma: 5-year surVIVOrs and their 6 to 10-year follow-up , 2006 .

[244]  A. Carrato,et al.  Therapy innovations: tyrosine kinase inhibitors for the treatment of pancreatic neuroendocrine tumors , 2011, Cancer and Metastasis Reviews.

[245]  G. Gaudernack,et al.  Long‐term follow‐up of patients with resected pancreatic cancer following vaccination against mutant K‐ras , 2011, International journal of cancer.

[246]  York Springer,et al.  Ajcc Cancer Staging Manual. 7th Ed. New , 2010 .